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Abstract
It is unclear if proximal and distal traditional adenomas present with differences in molecular 
events which contribute to cancer heterogeneity by tumor anatomical subsite. Participants from a 
colonoscopy-based study (n=380) were divided into subgroups based on the location of their most 
advanced adenoma: proximal, distal, or “equivalent both sides”. Eight biomarkers in the most 
advanced adenomas were evaluated by immunohistochemistry (Ki-67, COX-2, TGFβRII, EGFR, 
β-catenin, cyclin D1, c-Myc) or TUNEL (apoptosis). After an adjustment for pathological 
features, there were no significant differences between proximal and distal adenomas for any 
biomarker. Conversely, expression levels did vary by other features, such as their size, villous 
component, and synchronousness. Large adenomas had higher expression levels of 
Ki-67(P<0.001), TGFβRII (P<0.0001), c-Myc (P<0.001), and cyclin D1 (P<0.001) in comparison 
to small adenomas, and tubulovillous/villous adenomas also were more likely to have similar 
higher expression levels in comparison to tubular adenomas. Adenoma location is not a major 
determinant of the expression of these biomarkers outside of other pathological features. This 
study suggests similarly important roles of Wnt/β-catenin and TGF-β pathways in carcinogenesis 
in both the proximal and distal colorectum.
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INTRODUCTION
The colorectum is dichotomized as proximal and distal based on its embryonic origin and 
varying physiological functions and gene expression [1–3]. Data suggest that colorectal 
cancer (CRC), one of most common cancers [4], is highly heterogeneous by tumor subsite. 
For example, in comparison to distal CRCs, proximal CRCs exhibit a higher incidence in 
women and the elderly, a higher mortality [5,6], a different histopathological appearance [7], 
and a higher prevalence of some distinct molecular alterations such as microsatellite 
instability (MSI) [8,9]. Some of these differences may be attributed to sessile serrated 
adenomas (SSA), the presumed precursor for most MSI-high CRCs, which is more prevalent 
on the right colon than on the left colorectum [10,11]. However, it remains unclear whether 
there are molecular events that also affect the more common traditional or conventional 
adenoma and contribute to subsite heterogeneity in CRC.
Proximal adenoma prevalence is greater than distal adenomas among some subgroups, such 
as older adults, African-Americans and women [12–17]. Although small adenomas (< 10 
mm) are evenly distributed [18,19], advanced adenomas are more predominant in the distal 
colorectum [20–24]. A recent analysis of more than 1.2 million CRC cases suggested that 
adenoma initiation rates were higher for proximal tumors, whereas growth rates were higher 
for distal tumors [25]. However, despite substantial data regarding the correlation of 
adenoma localization with age, race, gender, and stage, little is known about possible 
underlying molecular events which may differentially contribute to the tumorigenic process. 
In this study, we compared a panel of biomarkers between proximal and distal adenomas. 
These biomarkers were selected because they have been reported to be important factors or 
pathways in colorectal tumorigenesis [26], including cell proliferation (Ki-67), apoptosis 
(terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)), 
cyclooxygenase-2 (COX-2), transforming growth factor beta receptor II (TGFβRII), 
epidermal growth factor receptor (EGFR), and Wnt/β-catenin pathway (β-catenin, cyclin D1 
and c-Myc).
MATERIALS AND METHODS
Participants
The subset of participants is from a retrospective cohort study, the Tennessee-Indiana 
Adenoma Recurrence Study [27]. Out of the 1643 eligible individuals, 1020 (62.1%) 
participated. Eligibility criteria were: their first adenoma diagnosis during index 
colonoscopy had to have taken place between January 1996 to December 2002; they had an 
index diagnosis of synchronous (>1) or advanced (≥1.0 cm in diameter, villous/
tubulovillious subtype, or high-grade dysplasia) adenoma; they were between the ages of 40 
and 75; there was an absence of familial adenomatous polyposis or previous history of 
cancer, except for non-melanoma skin cancer; they were not already participating in an 
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intervention trial to prevent adenoma recurrence; they had the ability to speak English and 
provide informed consent; they could not be a current resident in a correctional facility. 
Included in this analysis were the first 380 participants. In comparison to the entire cohort, 
individuals selected for this study were more likely to be female (39.2% vs 31.1%), white 
(89.5% vs. 80.6%), and less likely to have a large adenoma (28.7% vs. 34.8%). There were 
no statistically significant differences for age, the presence of synchronous adenomas, the 
location of the adenomas, the presence of the worst subtype, or the presence of high-grade 
dysplasia. Committees for the use of human subjects in research at each institution approved 
the study protocol.
Diagnosis data were abstracted from medical records. Formalin-fixed, paraffin-embedded, 
adenoma tissue blocks were obtained. 5 μm sections were made and placed on charged 
slides. Serial tissue sections were coated with a thin layer of paraffin and placed in a vacuum 
desiccator cabinet (Terra Universal Company, CA) at 4°C. The diagnosis was reviewed and 
confirmed by an experienced research pathologist (T.S.).
An analytic index adenoma was selected for each participant. If the participant had 
synchronous adenomas, the most advanced adenoma tissue was used, and was defined in the 
following order: 1) the presence of high-grade dysplasia, 2) the most villous component, or 
3) the largest size. According to the index adenoma location, the participant was defined as 
“predominant proximal” (in which the index adenoma was proximal to the splenic flexure) 
or “predominant distal” (in which the index adenoma was in the splenic flexure or distal to 
it). Fifty-eight participants with histopathologically equivalent adenomas on both sides were 
categorized as “equivalent both sides”, and both adenomas were used in the analysis.
Immunohistochemistry
The optimized staining protocols for Ki-67, cyclin D1, COX-2, EGFR, c-Myc, and TGFβRII 
are summarized in Supplementary Table 1. For negative controls, phosphate buffered saline 
(PBS) replaced primary antibodies. Both positive and negative control slides were processed 
with each batch of staining. The semi-quantitative scoring criteria for Ki-67, cyclin D1, 
COX-2 and EGFR were previously described [28]. The cut-off value for each biomarker was 
determined based on the protein expression level in adenoma tissue, as used in previous 
reports [29–33]. Briefly, Ki-67 was 0 (0–20% cells positive) and 1 (>20%) [28,29]. Cyclin 
D1 was recorded as 0 (<5% cells positive), 1 (5–30%), and 2 (>30%) [30]. COX-2 and 
TGFβRII were scored using a modified All red scoring system, which combines the 
estimated proportion of positive staining tumor cells with the average estimated intensity of 
staining [28,34]. EGFR was recorded as 0 (<10%), 1 (10–50%), and 2 (>50% )[31,32]. C-
Myc was scored 0 (0%), 1 (<10%); 2 (10–50%), and 3 (>50%) [35]. The superficial, middle 
and basal thirds of polyps were also scored separately for zonal scores, using the same 
criteria as for the entire polyp.
Immunohistofluorescence
Our previous validation study showed a complex subcellular localization of β-catenin, which 
may exist in the nucleus, in the cytoplasm, or on the cell membrane [28]. It is generally 
accepted that β-catenin can function as an oncogene when it is translocated from membrane 
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to nucleus, when it binds to T cell factor (TCF) or lymphocyte enhance family members, and 
when it transactivates its target genes [33]. In this study, fluorescence immunohistochemistry 
was performed to determine β-catenin nuclear accumulation and co-expression of 
transcription factor 4 (TCF4), so that the nuclear localization of β-catenin could be more 
clearly visualized than is possible with the conventional immunohistochemistry method. An 
optimized double immunofluorescent labeling protocol was performed. The deparaffinized 
slides were placed in R-buffer A and heated with a pressure cooker for antigen retrieval. The 
sections were incubated with 5% normal donkey serum for 10 min at 37°C, then by the 
primary antibody mixture of goat anti-TCF4 (Santa Cruz, Cat# sc-8631, 1:80) and mouse 
anti-β-catenin (BD Transduction Lab, Clone 14,1:200 ) for 1 hour at room temperature. 
After a rinse in PBS, sections were incubated with biotin conjugated anti-mouse (R&D, Cat# 
CTS002) for 30 minutes to amplify the β-catenin signal. After a thorough rinse in PBS, 
sections were incubated with a mixture of streptavidin-FITC (Zymed, Cat# 43-8311, 1:80) 
and Cy3 conjugated donkey anti-goat (Chemicon, Cat# AP180C, 1:100) for 30 minutes. 
After another thorough rinse, the sections were coverslipped with ProLong Gold Antifade 
Reagent with DAPI (Invitrogen, Cat# P36935) and stored in the dark at 4 °C. Known 
positive adenoma tissue was used as a positive control. Negative controls were made by 
replacing primary antibodies with PBS. Nuclear or cytoplasmic immunostaining were 
considered equally as positive signals. Nuclear β-catenin accumulation in tumor cells was 
scored according to a four-category (0–3) method (Supplementary Figure 1). Nuclear TCF4 
was not recorded because of its widespread expression in all nuclei of adenoma epithelial 
cells.
Apoptosis Assay
Apoptosis was detected with the Promega DeadEndTM Colorimetric Apoptosis Detection 
System (Promega BioScience, CA), which is based on a modified TUNEL assay. The 
positive control was human liver, and the negative control was obtained by omitting the TdT 
enzyme after peroxidase inactivation. To accurately record the apoptotic index (the 
percentage of TUNEL-positive cells versus the total number of cells) [36], computer-aided 
quantitative analysis was performed with an Olympus BX40 microscope, a Retiga FAST 
1394 color digital camera and BioQuant NOVA Prime imaging software (BioQuant, TN). 
Positive cells in the adjacent stroma were excluded, or if they were into the luminal space, if 
they were blank, folding, hemorrhaging, experiencing necrosis, poorly stained, and if they 
were in stromal areas. The quantitative imaging analysis method is summarized in 
Supplementary Figure 2.
Statistical Analysis
The chi-square test and the student’s t-test were used to analyze the characteristics of 
participants and the expression of biomarkers between predominant proximal and 
predominant distal adenomas. To compare the expression between proximal and distal 
adenomas in the “equivalent both sides” subgroup, Wilcoxon-signed rank tests or paired 
students’ t-tests (TUNEL only) were used. Analysis of variance was used for the 
comparisons involving more than three groups. The intraclass correlation coefficient was 
used to evaluate intra-observer variations of TUNEL. The correlations of the eight markers 
were also analyzed using Spearman correlation coefficients. In analyses including all 
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participants, the mean scores of distal and proximal adenomas were calculated for the 
“equivalent both sides” subgroup. All analyses were two-sided, with a significance level of 
5% and performed using SAS statistical software (v9.3).
RESULTS
Most participants had traditional and synchronous adenomas (Table 1). The predominant 
distal group was more likely than the predominant proximal group to have a large or 
advanced adenoma (P<0.001) or villous histology (P=0.03), and was less likely to have 
synchronous adenomas (P<0.001).
The typical distribution of positive cells and subcellular localization patterns had apparent 
differences by zonal location (Figure 1 and Supplementary Table 2). Except for c-Myc, 
EGFR and TUNEL, biomarker expression varied by adenoma characteristics (Table 2). 
When there were differences between adenoma types, in general, the more severe phenotype 
had a higher expression level than the less severe phenotype. For example, compared to 
small adenomas, large adenomas had higher expression levels of Ki-67, TGFβRII, c-Myc, 
and cyclin D1 (all P<0.001), as well as a higher Wnt pathway score (P=0.008). Adjustment 
for their location in the colon did not alter results (data not shown). To evaluate the 
individual contributions of synchronousness and histology to the observed differences, we 
compared the expression between individuals with synchronous non-advanced adenomas 
with a single advanced adenoma, and with at least one advanced adenoma in addition to 
synchronous adenomas. Ki-67, COX-2, TGFβRII β-catenin, c-Myc, Cyclin D1, and the Wnt 
pathway score were significantly different between the groups. Expression levels of these 
markers were higher among those with advanced adenomas regardless of the number of 
adenomas, with the exception of TGFβRII.
Compared to the predominant proximal group, the predominant distal group had 
significantly stronger expression of cyclin D1 (P=0.01) and EGFR (P=0.05) (Table 3). There 
was no significant difference between the groups for the other markers. After an adjustment 
for pathological features, there were no significant differences in expression for all markers 
between predominant proximal and predominant distal adenomas. This was also confirmed, 
with one exception, in an exploratory analysis comparing colon versus rectum differences. 
This was done by evaluating the proximal colon versus the distal colon (i.e. excluding rectal 
adenoma, data not shown) or by comparing the proximal colon, distal colon, and rectum. C-
Myc levels were higher in rectum adenomas versus distal and proximal adenomas (P=0.02; 
data not shown). In a model in which all five biomarkers with a P <0.20 from the unadjusted 
models (c-Myc, cyclin D1, EGFR, β-catenin, and TGFβRII) were mutually adjusted for 
each other, there were no significant differences in expression between predominant 
proximal and predominant distal adenomas for all five of the markers.
Within the “equivalent both sides” group, the expression levels of all markers were similar 
between distal and proximal adenomas(Table 4), except for cyclin D1, which showed a 
higher expression level in the predominant distal adenoma in unadjusted analysis (P=0.03) 
and its Wnt pathway score (P=0.045). However, after an adjustment for adenoma size, 
subtype, degree of dysplasia, and synchronousness, there were no differences between 
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proximal and distal adenomas (data not shown in table). Most biomarkers were significantly 
correlated with each other, except for nuclear β-catenin, which only correlated with c-Myc 
expression (P=0.03) (Table 5).
DISCUSSION
We found no differences between proximal and distal adenomas in a panel of eight 
biomarkers involved in colorectal tumorigenesis after adjusting for other adenoma features. 
This held true whether comparing adenomas from different individuals or different 
adenomas within the same person, indicating a similar tumorigenesis process within 
traditional adenoma subtypes regardless of tumor location. The tumorigenesis process might 
be similar throughout the colorectum for sporadic traditional adenomas, at least as it relates 
to this panel of biomarkers. This study suggests that the TGF-β and Wnt/β-catenin pathways 
play important roles in both proximal and distal colorectal tumorigenesis, and that a 
synergistic role in the TGF-β, Wnt/β-catenin, COX-2 and EGFR pathways may exist to 
promote tumor progression throughout the human colorectum. This may have important 
implications for CRC prevention.
The proximal and distal segments develop from two embryonic areas with different 
physiological functions, and have different gene expression levels [1,2]. A large body of 
CRC and adenoma studies also support differences between segments in epidemiology, 
clinicopathology and molecular biology [5–9,37–40]. These findings suggest that there 
might be location-related molecular features in normal colorectum and neoplastic lesions. In 
recent years, some of these differences have been identified to be related to the serrated 
neoplasia pathway [11,41]. Thus far, little is known about underlying molecular events, 
other than the serrated neoplasia pathway, which may differentially contribute to the 
tumorigenic progress in traditional adenomas arising in the proximal versus distal 
colorectum. The current study, limited to comparisons of traditional adenomas, did not find 
differential expression for the selected biomarkers involved in cell proliferation/apoptosis 
and the signaling pathways of COX-2, TGFβ, EGFR, and Wnt/β-catenin. Our results are 
consistent with reports that non-steroidal, anti-inflammatory drug use is associated with a 
reduced risk of adenoma recurrence by a similar magnitude in both the distal and proximal 
colon [41], and that risk factors for traditional adenomas are largely similar between the 
proximal and distal colorectum [42]. In addition, nuclear β-catenin overexpression had no 
correlation with the CRC tumor site in a recent meta-analysis [43]. However, due to the 
substantial variability of molecular events in CRCs and the hundreds of potential alterations, 
we cannot definitively conclude that there is no heterogeneity for any biomarker between the 
proximal and distal colorectum based on our limited analysis of the eight biomarkers in this 
study. For example, a recent study reported distinct patterns of DNA methylation between 
traditional adenomas of the proximal and distal colon [44]. Nevertheless, this study has 
opened the way for further studies involving more (or other) pathways, other methods, or 
other types of markers (e.g. DNA mutations, DNA methylation, non-coding RNAs, etc) 
which may provide additional molecular evidence to clarify the potential tumorigenic 
differences between proximal and distal adenomas.
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Although polyp location was not associated with the expression of biomarkers evaluated in 
this study, we did observe that other important clinicopathological features of adenomas, 
such as tumor size, villous component, dysplasia, and synchronousness were significantly 
associated with the biomarker expression. This is consistent with previous studies. For 
example, in the Wnt/β-catenin pathway, nuclear β-catenin was significantly associated with 
high grade dysplasia or advanced adenomas, consistent with other reports regarding its key 
role in promoting an adenoma’s progression to carcinoma [45–48]. The expression of 
nuclear cyclin D1, a responsive gene of the Wnt/β-catenin pathway, was significantly higher 
in advanced adenomas. These adenomas have higher cellular proliferation, larger size, and a 
higher villous component than in non-advanced adenomas. This is consistent with its 
potential role in adenoma progression [49–51]. The protein expression of c-Myc, another 
important target gene of the Wnt/β-catenin pathway, has been reported to be closely 
correlated with the size of a colorectal adenoma [45]. In general, we also found that 
expression levels were higher in more advanced adenomas, although this was not 
statistically significant for the villous component. C-Myc is not necessarily correlated with 
cellular proliferative activity in previous studies [45,52], but we observed a positive 
correlation between the c-Myc and Ki-67 levels in this study. We also found that, of all the 
markers, c-Myc might be the only one with location-specific expression (with higher levels 
in the rectum). Given the important role of Myc-directed transcriptional activation in CRCs 
[53] and the prevalence of expression in our study, our findings suggests that c-Myc 
overexpression might be a later-stage event than cyclin D1 in colorectal carcinogenesis [54].
In this study, TGFβRII expression was positively associated with more advanced adenomas, 
including the phenotypes of large, villous, and high-grade dysplasia. The epithelial cells in 
the adenomas were heterogeneously expressed with patchy strong staining and with zonal 
specificity at the surface, unlike the normal colonic mucosa, which shows a uniform 
distribution of TGFβRII expression in a moderate level in normal colon epithelial cells and 
stromal cells [55]. This finding suggests that the dysregulation of the TGF-β pathway in 
colorectal adenomas includes an abnormal TGFβRII expression, exhibiting a decreased 
expression in some tumor cells and an increased expression in other cells. In general, the 
increased expression of TGFβRII protein is associated with more advanced pathologic 
features of adenomas. Interestingly, out of eight selected biomarkers, only decreased 
TGFβRII was significantly associated with adenoma synchronousness. This suggests that 
reduction in TGFβRII may contribute to the initiation of colorectal adenomas. Our 
observations provide data to support the importance of the dysregulation of the TGFβ 
pathway in colorectal carcinogenesis in humans.
In addition to the Wnt/β-catenin and TGFβ pathways, the COX-2 pathway also has a key 
role in colorectal carcinogenesis, based on evidence from both animal and human studies 
[56,57]. Specifically, the administration of the COX-2-selective inhibitor celecoxib 
significantly decreases the occurrence of sporadic colorectal adenomas, not only by 
suppressing the growth of existing adenomas, but also by preventing the formation of new 
adenomas [58]. A previous study reported that large (> 1 cm) adenomas exhibited a 
significantly stronger expression of COX-2 than the very small (< 5 cm) adenomas, and an 
expression was absent in normal colonic epithelium, suggesting that epithelial COX-2 
activity is important for the growth and/or survival of adenomatous epithelial cells [59]. 
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Although we did not observe a statistically significant difference according to the size of the 
adenomas in this study, we did find levels were higher in adenomas with a villous 
component or high-grade dysplasia. This is consistent with this statement. However, there 
may be important tumor-stromal interactions at the adenoma stage of neoplasia. Individuals 
with a high deep stromal expression of COX-2 developed significantly more recurrent 
adenomas (65%) than those with a low deep stromal expression (47%, p=0.04) [60]. Further, 
although much of the data suggest an important role for COX-2/PGE2 signaling in the 
promotion of tumorigenesis, many conflicting results have also been reported and further 
research is still required [61]. Our data supports the role of COX-2 in tumor progression in 
the human colorectum, but also indicates it may not be as important as the TGF-β and Wnt/
β-catenin pathways. Future large-scale studies with detailed zonal quantitative analysis of 
epithelial/stromal expression of COX-2 may contribute to understanding the precise role of 
COX-2 in human colorectal carcinogenesis.
In addition to evaluating the individual markers within a pathway, it is also important to 
consider their relationship to each other because cancer development is a long-term, 
complex process requiring an accumulation of alterations in multiple genes and signaling 
pathways to form a complex cross-talk network. In the present study, most biomarkers were 
significantly correlated with each other. For example, cyclin D1 was also significantly 
correlated with other biomarkers such as Ki-67, EGFR, TGFβRII and c-Myc, suggesting a 
complexity of potential interactions of cyclin D1 with other genes, regardless of tumor 
location [62]. An illustration summarizing the relationships between the pathways examined 
in this study is provided in Figure 2. Previous animal studies using mouse models of 
Smad4/APC and Smad2/APC compound heterozygotes provided direct evidence of the 
cooperative involvement of TGF-β and Wnt signaling in carcinogenesis, including colon 
neoplasia [63,64]. The exact nature of the signaling cross-talk among the pathways is 
extremely complex and highly context-dependent. Nonetheless, it is well-described that the 
Wnt/β-catenin signaling plays a key role in both early and late colorectal tumorigenesis [65] 
[53]. Furthermore, this pathway interacts with other pathways to form complex signaling 
networks (see reviews [66–71]). The β-catenin downstream targets (cyclin D1 and c-Myc) 
are not only regulated by the Wnt/β-catenin pathway, but also directly (EGFR) and 
indirectly (EGFR, TGF-β, and COX-2) by other pathways. For example, EGFR-Erk directly 
increases the expression of cyclin D1 and c-Myc and indirectly enhances β-catenin-TCF 
transcription activity by down-regulating caveolin-1. The nuclear pSmad2/3 can directly 
associate with the lymphoid enhancer binding factor 1/T cell-specific factor (LEF1/TCF) to 
synergistically activate β-catenin target genes. This may partially explain our finding that, in 
comparison to β-catenin, its downstream targets (cyclin D1 and c-Myc) and cell proliferation 
activity (Ki-67) are more closely correlated with the other pathway biomarkers EGFR, 
COX2 and TGFβRII. However, this study showed that nuclear accumulation of β-catenin is 
associated with its downstream target gene c-Myc, but not cyclin D1. The lack of a 
correlation between nuclear cyclin D1 and nuclear β-catenin might be explained by a 
previous study. It found that the nuclear accumulation of cyclin D1 is mainly due to the loss 
of cyclin D1 nuclear export, altered nuclear trafficking, and proteolysis. This can result from 
direct mutations within cyclin D1, cancer-specific alternative splicing or mutations that 
target the upstream signaling pathway that regulate the phosphorylation-dependent nuclear 
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export of cyclin D1 complexes [72]. Although larger studies are needed, our observational 
data provide support that, for traditional sporadic adenomas, a synergistic role among Wnt/
beta-catenin, TGF-β, COX-2 and EGFR pathways may exist to promote tumor progression 
in the colorectum. Thus, multiple and key components in the associated pathways likely 
need to be simultaneously targeted for use as early detection biomarkers or for the effective 
prevention and treatment of CRC.
To the best of our knowledge, few studies focus on the comparison of the expression of 
carcinogenesis biomarkers in traditional colorectal adenomas between the proximal and 
distal colorectum. For this study, there are several factors that need to be considered in the 
interpretation. This study only included individuals with either synchronous or advanced 
adenomas, so this study may represent a more severe, or later, phenotype. This study was 
also limited to an analysis of combined categories of colorectum segments (i.e. proximal and 
distal or distal without rectum). If there are important location differences in early 
carcinogenesis or if there are important segmental differences, this study may not have been 
able to detect the differences. In this study, we used non-probability sampling within a larger 
cohort. Although we found few differences between the sample and the larger cohort, we 
cannot exclude the possibility of unmeasured selection biases or confounding, which may 
affect the generalization to the larger cohort in an unknown manner. The study is also based 
on a cross-sectional analysis and so cannot evaluate relationship or relevance of the selected 
markers to the prospective risk of colorectal neoplasia. The panel of markers was carefully 
selected for this study based on known genes and pathways important in the initiation and 
progression of CRC [26]. Although we did not observe statistically significant differences 
between proximal and distal adenomas in this study for any of the eight selected biomarkers, 
we did observe differences according to other adenoma features, such as advanced adenoma. 
Future studies are warranted to evaluate whether these markers may be used as predictors of 
advanced adenoma. Future studies in probability-based samples, which can also 
prospectively evaluate risk of metachronous adenoma or colorectal cancer and more 
extensive biomarkers, are also needed to confirm or refute our findings.
There are several strengths. Participants were recruited from a well-established retrospective 
cohort study of patients with a first time diagnosis. We had detailed patient information, and 
the diagnoses were standardized by a single pathologist. Our results with adenoma features, 
other than polyp location, were consistent with most previous studies, suggesting the data 
obtained in the current study are appropriate for the analyses. Finally, in general, the sample 
size was adequate for most comparisons, although the number of adenomas with high grade 
dysplasia was small.
In conclusion, our study indicated that the expression of selected biomarkers were largely 
similar between distal and proximal adenomas, after accounting for histological differences, 
indicating a similar carcinogenesis process in traditional adenoma formation for our study 
participants. The altered expression of β-catenin, cyclin D1 and TGFβRII was closely 
correlated with advanced features of adenoma, suggesting the important roles of Wnt/β-
catenin and TGF-β pathways in the carcinogenesis in both the proximal and distal 
colorectum. Further studies are warranted to confirm our findings.
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Figure 1. 
The expression patterns of eight markers in colorectal adenomas. The positive cells of most 
markers (Ki-67, TUNEL, COX-2, cyclin D1, EGFR, c-Myc and TGFβRII) show surface 
predominant distribution, except nuclear β-catenin (h), which shows basal predominant 
distribution (in which the positive cells are mainly distributed in the basal zone of 
adenomatous polyp) (see Supplementary Table 2). The subcellular localization of each 
marker is shown with high-power magnification in the lower right corner of each figure. The 
positively stained markers may present in the nuclei (Ki-67, TUNEL, cyclin D1 and c-Myc), 
cytomembrane (TGFβRII and EGFR), or cytoplasm (COX-2) of tumor cells. The positive 
signal of β-catenin shows the complexity of subcellular localization in the cell membrane, 
cytoplasm and nuclei (h). The positive nuclear β-catenin (green) overlaid the positive TCF4 
(red) shows in yellow color, and the nuclei are counterstained with DAPI.
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Figure 2. The cross-talk of the canonical Wnt/β-catenin pathway with the TGF-β, EGFR and 
COX-2 pathways
For the interaction between the Wnt/β-catenin and TGF-β pathways, the responsive Smads 
(Smads 2 and 3) can directly associate with lymphoid enhancer binding factor 1/T cell-
specific factor (LEF1/TCF) to synergistically activate target genes [73,74]; the tumor 
suppressor Smad4 is negatively regulated by Wnt/GSK3 phosphorylations [75]; Axin, a core 
component of the β-catenin destruction complex, may function as an adapter, facilitating 
Smad3 association with the receptor complex thereby promoting TGF-β signaling [76]; 
FOXQ1, a member of the forkhead transcription factor family, can be induced by TGF-β1 
and enhance the nuclear translocation of β-catenin [77]. For interaction between Wnt/β-
catenin and EGFR pathways, a synergistic interaction has been found through various 
mechanisms at different levels. For example, the direct association between β-catenin and 
EGFR/c-Neu (ErbB1/ErbB2) heterodimers is identified in mammary gland tumors [78]. In 
intestinal tumor cells, APC and KRAS act synergistically in enhancing Wnt signaling, tumor 
formation and progression [79]. Overexpression of Wnt-1 and Wnt-5a activated EGFR 
signaling by stimulated EGFR tyrosine phosphorylation, activation of extracellular signal-
regulated kinase (ERK)1/2, and matrix metalloproteinase-mediated release of soluble EGFR 
ligands through Frizzled receptors [80]. A potent activation of Wnt/β-catenin by EGFR is 
dependent on ERK MAP kinase-mediated phosphorylation of Wnt co-receptor LRP6 which 
dramatically increases the cellular response to Wnt. Moreover, EGFR directly phosphorylate 
β-catenin at Tyr142, which is known to increase cytoplasmic β-catenin concentration via 
release of β-catenin from membranous cadherin complexes [81]. The phosphatidylinositol 3-
kinase (PI3K)/AKT pathway inactivates GSK3, via direct AKT-mediated phosphorylation to 
facilitate Wnt signaling pathway [82]. EGF treatment of human breast cancer cell lines 
MDA-MB-468 can induce a strong tyrosine phosphorylation of β-catenin, that blocks the 
interaction between β-catenin and E-cadherin and increases the invasiveness and metastatic 
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potential of cancer cells [83]. In addition, EGFR/Erk signaling causes upregulation of cyclin 
D1 and c-Myc, and downregulation of caveolin-1 which in turn enhances β-catenin-TCF/
LEF-1 transcriptional activity [84–86]. For interaction between Wnt/β-catenin and COX-2 
pathways, a direct link between two pathways has been found through prostaglandin E2, one 
of the bioactive products of COX-2, which activates components of the canonical Wnt 
signaling system via G protein-coupled receptor EP2 and ravious signaling. The G protein α 
subunits (Gαs) interact with Axin resulting displacement of APC and increase of nuclear β-
catenin; Gαs can also activate Akt through PKA; G protein βᵞ subunits (Gβᵞ) interact with 
PI3K resulting phosphorylation and inactivation of GSK-3β via Akt. In addition, EP2-Gβᵞ 
can also promote the transactivation of EGFR pathway in colon cancer cells through Src, 
which activates the proteolytic release of the EGFR ligands amphiregulin (AR) and 
transforming growth factor-α (TGFα), thereby stimulating the EGFR-signalling network. 
EP2-Gαs also stimulates expression of COX-2 by activating adenylyl cyclase (AC), resulting 
in increased cyclic AMP (cAMP) production, protein kinase A (PKA) activation and the 
phosphorylation of CREB. [69,71].
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